Global Immunology Drug Market Research Report 2022

The immune system is an assembly of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies various threats like bacteria, viruses, and parasites and distinguishes them from body's healthy tissues. When the immune system weakness and lose the capability to detect and destroy the abnormal cells or body attacks and damages its tissues lead to diseases like cancer and autoimmune diseases. Immunotherapy is a process which includes the treatment by inducing, enhancing or suppressing an immune system to fight against the diseases.
Due to the COVID-19 pandemic, the global Immunology Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Immunology Drug market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Immunology Drug landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Monoclonal Antibodies (mAb) accounting for % of the Immunology Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Immunology Drug include Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune Inc., Pfizer, GlaxoSmithKline plc, Seattle Genetics, Genentech and F. Hoffmann-La Roche Ltd., etc. In terms of revenue, the global 3 largest players have a % market share of Immunology Drug in 2021.
This report focuses on Immunology Drug volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Immunology Drug market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Immunology Drug Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Monoclonal Antibodies (mAb)
Antibody Drug Conjugates
Immunosuppressive medication
Others
Segment by Application
Hospitals
Clinics
Cancer Research Centers and Institutes
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Abbott Laboratories
Active Biotech
Eli Lilly and Company
Autoimmune Inc.
Pfizer
GlaxoSmithKline plc
Seattle Genetics
Genentech
F. Hoffmann-La Roche Ltd.
Eisai Co.
Bayer AG
Sanofi Aventis LLC.

Frequently Asked Questions